This site is intended for health professionals only

Sunday 19 May 2019
Share |

Topic: Connective tissue disorders

April 8, 2019
Research on the X chromosome has pointed to an abnormality in the immune system's T cells as a possible factor in lupus and other autoimmune diseases
Eighty-five percent of people with lupus are female, and their second X chromosome seems partly to blame. 
 
According to a new study by researchers at the University of Pennsylvania, females with lupus do not fully "silence" their second X chromosome in the immune system's T cells, leading to abnormal expression of genes linked to that chromosome.
 
April 2, 2019
The SLE populations of the pivotal BLISS-52 and BLISS-76 trials constitute large patient cohorts, ideal for post-hoc survey to better understand the disease itself, and the effects of belimumab treatment
The treatment of systemic lupus erythematosus (SLE) has traditionally been non-specific, comprising glucocorticoids, non-steroidal anti-inflammatory drugs and broad immunosuppressive agents.
 
The monoclonal antibody belimumab towards the soluble counterpart of the B cell activating factor belonging to the tumour necrosis factor family (BAFF), also known as B lymphocyte stimulator (BLyS), is the only targeted therapy approved by regulatory agencies for SLE, and has been available for use since 2011.1
March 28, 2019
Patients with lupus are on average seven to nine times more likely to develop heart disease than the general population, and younger women with lupus are 50-times as likely to develop the disease as young women without the disease
 
A research team at the Medical University of South Carolina (MUSC) has shown that the enzyme responsible for nitric oxide production stops working properly when exposed to serum from lupus patients. They also showed that its ability to produce nitric oxide can be restored by administration of L-sepiapterin. Their findings are published in an article published ahead of print in Lupus Science & Medicine.1
 
March 8, 2019
A study funded by the Lupus Research Alliance shows that depleting the number of harmful B cells with a novel immunotherapy that employs CAR T-cells might offer an effective strategy to treat lupus
Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a study funded by the Lupus Research Alliance. 
 
These findings offer a renewed optimism for the elimination of B cells to provide a therapeutic option in lupus and pave the way for clinical research to test this new approach.
 
March 1, 2019
A protein known to play a role in cancer may also be increasing fibrosis in scleroderma patients
In a recent study, published in Proceedings of the National Academy of Sciences, Amr Sawalha MD, a professor in the Division of Rheumatology at the University of Michigan and his team examined scleroderma at the molecular level to better understand the fibrosis process.1
 
February 20, 2019
While bacterial imbalances have been tied to many immune-related diseases, authors of a new study say their experiments are the first detailed evidence of a link between bacterial imbalances in the gut and potentially life-threatening forms of systemic lupus erythematous
Systemic lupus erythematosus (SLE) is linked to an abnormal mix of bacteria in the gut according to a new study led by scientists at NYU School of Medicine.
 
The study, published in the Annals of Rheumatic Diseasesshowed that 61 women diagnosed with SLE had roughly five times more Ruminococcus gnavusgut bacteria than 17 women of similar ages and racial backgrounds who did not have the disease and were healthy.1 Lupus is more common in women than in men.
 
January 7, 2019
NOVESA is planned to recruit 30 patients with diffuse cutaneous systemic sclerosis, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases
Galapagos NV has expanded its clinical study program with GLPG1690 in systemic sclerosis (SSc), following the recent start of the ISABELA Phase III program with ’1690 in idiopathic pulmonary fibrosis (IPF).
 
December 21, 2018
The Award encourages exceptional investigators worldwide to pursue innovative research projects that pair unconventional creativity with sound science to uncover the fundamental causes of lupus

The Lupus Research Alliance has announced the 2018 recipients of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: namely, Nir Hacohen, PhD and Vijay Kuchroo, DVM, PhD.

December 17, 2018
Early diagnosis is mandatory in order to start treatment before irreversible tissue damage takes place and this approach results in a better prognosis (that is, less organ damage) and in reduced costs of the disease

 

December 6, 2018
Harmonisation of the diagnostic performance of existing serological assays, finding novel markers to reduce the diagnostic limitation of seronegativity and exploring the predictive value of autoantibodies are the major goals of serodiagnostic research in rheumatoid arthritis

Rheumatoid arthritis (RA) is a prevalent chronic inflammatory autoimmune disease mainly characterised by joint swelling and pain, affecting approximately 0.5–1% of the population in industrialised countries.1

December 6, 2018
Observations from a Phase II trial support further development of ustekinumab as a new therapy for SLE, and results from Phase III trials are awaited

Development of treatments for systemic lupus erythematosus (SLE) has been challenging.

Many components of the immune system have been identified as targets for novel therapies, but the majority of the clinical trials have failed. However, many trials are ongoing and some of them have reported promising preliminary results.

October 2, 2018
In March 2017, the landscape changed significantly for the Ehlers-Danlos syndromes and the newly described hypermobility spectrum disorders
In the last decade, growing attention has been placed on joint hypermobility and related disorders, but the Ehlers-Danlos syndromes (EDS) have fascinated people throughout the ages. The first report of this disorder dates back to Hippocrates (fourth century BC). For many centuries, affected individuals earned their livings as The Elastic Skin Man, The India Rubber Man and The Human Pretzel, amazing their audiences in fairgrounds and circus side shows by exhibiting contortionist tricks and a remarkable ability to stretch their skin.1
 

October 2, 2018
This review focuses on novel treatments in the management of myositis, incuding recent clinical trial data
Idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune muscle disorders including polymyositis (PM), dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM) and possibly inclusion body myositis (IBM). There are some similarities in clinical presentation with proximal symmetric muscle weakness in PM, DM and IMNM; with the exception of IBM, which presents with distal arm and proximal leg asymmetric muscle weakness, finger flexor and knee extensor weakness being characteristic early clinical features of the disease. 
 
October 2, 2018
There is now a better understanding of autoimmunity in systemic lupus erythematosus, which has led to improved therapeutic strategies, but revolutionary treatments have yet to be discovered
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disorder that predominantly affects women of child-bearing age with a ~9:1 female-to-male ratio. Patients with SLE suffer an impaired health-related quality of life (HRQoL), and experience fatigue and pain as major problems. 
 
November 9, 2017
Ustekinumab showed significant improvements in various disease measures compared with placebo, including musculoskeletal, mucocutaneous, immunological markers and flares

Janssen has announced positive results from a randomised, placebo-controlled Phase II study investigating the anti-interleukin (IL)-12/23 monoclonal antibody Stelara® (ustekinumab) in the treatment of active systemic lupus erythematosus (SLE or lupus).

May 8, 2017
New website launched on International Viking Day to support awareness of Viking disease

Today, on International Viking Day, Sobi is launching www.thisisdupuytrens.com to raise awareness of Viking disease, also known as Dupuytren’s disease.

May 13, 2016
On World Lupus Day the National Institute for Health and Care Excellence (NICE) announced a positive recommendation for GSK’s Benlysta® (belimumab) for use in adult patients with active autoantibody positive systemic lupus erythematosus (SLE or ‘lupus’) with a high degree of disease activity despite standard therapy

On World Lupus Day the National Institute for Health and Care Excellence (NICE) announced a positive recommendation for GSK’s Benlysta® (belimumab) for use in adult patients with active autoantibody positive systemic lupus erythematosus (SLE or ‘lupus’) with a high degree of disease activity despite standard therapy.1